Stockbridge to head Cardio-Renal permanently
Executive Summary
Norman Stockbridge is appointed permanent director of the Center for Drug Evaluation & Research's Division of Cardiovascular and Renal Products. Stockbridge has been serving as acting director since Douglas Throckmorton became CDER deputy director in May 2004 (1"The Pink Sheet" April 19, 2004, p. 4). Stockbridge joined FDA in 1991 as a medical officer and was appointed Cardio-Renal division deputy director in 2002...
You may also be interested in...
FDA Cardio-Renal Head Throckmorton Moves Up To Acting Deputy Of CDER
FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is moving up to the position of acting deputy director of CDER, effective May 3
What’s Next? Five Things To Look Out For In March
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
Sensyne Algorithm For COVID-19 Risk Prediction Gets UK Regulatory Approval
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: